The analyses, conducted in collaboration with Tempus AI, demonstrate that MUC16 expression remains high and stable across various standard-of-care regimens, including platinum-based chemotherapy and PARP inhibitors. Researchers noted that MUC16 displays less treatment-associated variation compared to other ADC targets like FRα, TROP2, and NaPi2b. These findings provide a scientific foundation for the clinical development of HWK-016, the company's next-generation ADC currently in Phase 1 trials.

Separately, data on high-grade serous ovarian carcinoma—the most common ovarian cancer subtype—revealed that elevated MUC16 levels correlate with poor real-world overall survival. According to Dr. Robert L. Coleman of Texas Oncology, this association persists even in treatment-naïve patients, marking MUC16 as a significant indicator of aggressive disease biology. The company intends to use these insights to refine its strategy for HWK-016, aiming for both combination therapies and applications in relapsed settings.